Poster Topical Area: Aging and Chronic Disease

Location: Auditorium

Poster Board Number: 27

P01-006 - Evaluation of Selected Natural Products for their Efficacy to Promote Androvitality by Inhibiting PDE5 and Augmenting Nitric Oxide (NO) Signaling

Sunday, Jun 10
8:00 AM – 6:00 PM

Background and Aims: To promote androvitality in men – energy, strength, vigor, cardiovascular health and sexual vitality -- a variety of influential cellular functions can be enhanced. Attempts to optimally enhance NO signaling while inhibiting phosphodiesterase5 (PDE5) have demonstrated clinical benefits in cardiovascular, sexual performance and reproductive health. NO released by endothelial cells, activates guanylyl cyclase leading to the accumulation of cGMP, responsible for the myriad biological actions attributed to NO. PDE5 breaks down to cGMP to GMP by modulating NO signaling. The objective of this study was to evaluate 20-proprietary natural product-based formulation(s) for their efficacy to augment NO signaling and inhibit PDE5 in cultured human cells.
Methods:
Twenty formulations were formulated and characterized by Purity Products R&D team (Plainview, NY). Human umbilical vein endothelial cells (HUVECs) were cultured to confluence and rendered quiescent by serum starvation prior to treating with test compounds at two concentrations (0.1 mg/mL and 0.25 mg/mL) for 24h. Following incubation, the media was aspirated and levels of nitrate/nitrite in the media was measured colorimetrically. cGMP levels were determined in cell lysates using a commercially available kit. The ability of the compounds to inhibit PDE5 activity in vitro was determined by evaluating its ability to inhibit the formation of convert 3',5'-cGMP substrate to GMP.
Results:
Interestingly, a couple of them showed varying ability to enhance NO signaling. Among them, Formula#X exhibited a significant increase in nitrate/nitrite levels and was also more effective in augmenting cGMP levels, while, Formula#Y was more efficacious in inhibiting the activity of recombinant PDE5.
Conclusion:
Formula#X may serve as an effective agent for augmenting NO signaling. Thus, a novel, exclusive combination of Rhaponticum and selected phytopharmaceuticals (StrongDrive®, patent pending) may serve as a novel formulation to enhance androvitality, by boosting NO signaling and modulating recombinant PDE5 activity.




Funding Source: The project was funded by Purity Products, Plainview, NY

CoAuthors: Rui Guo – University of Wyoming School of Pharmacy; Sreejayan Nair, PhD, FACN, FAHA – University of Wyoming College of Pharmacy; Jason Kam – Purity Products; Jahn Levin – Purity Products

Manashi Bagchi

Chief Research Officer
Dr. Herbs LLC
Concord, California